Clinical Trials Logo

Ischemic Stroke clinical trials

View clinical trials related to Ischemic Stroke.

Filter by:

NCT ID: NCT06120725 Completed - Ischemic Stroke Clinical Trials

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Start date: September 1, 2021
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06098066 Completed - Ischemic Stroke Clinical Trials

Decoding Risks and Rewards in Ischemic Stroke Surgery

Start date: May 1, 2020
Phase:
Study type: Observational

In the high-stakes battle against ischemic cerebrovascular disease, where every second counts and the margin for error is slim, how do the investigators tip the scales in favor of patient survival and improved outcomes? This groundbreaking study, the first nationwide, population-based analysis with long-term follow-up in an Asian context, dives deep into this critical question. Leveraging an expansive dataset from Taiwan's National Health Insurance Research Database, the investigators scrutinize the efficacy and risks of aggressive surgical interventions-specifically, EC-IC bypass, CEA, and CAS-in a cohort of over 84,000 patients. This paper serves as a milestone, bridging the gap between medical idealism and clinical reality. It calls for a surgical renaissance, emphasizing the need for refining techniques and enhancing patient selection protocols. If participants're looking for a comprehensive, nuanced, and, above all, actionable insight into the surgical treatment of ischemic cerebrovascular disease, this is the study that could redefine the paradigm.

NCT ID: NCT06078917 Completed - Clinical trials for Endovascular Treatment

Endovascular Treatment for AIS in Chinese Municipal and County Hospitals: A "Real World" Study-ETERNITY Registry

Start date: November 1, 2021
Phase:
Study type: Observational [Patient Registry]

To investigate the Endovascular Treatment difference between Chinese city and country hospital.

NCT ID: NCT06058884 Completed - Ischemic Stroke Clinical Trials

Predictors of AIS Unfavorable Outcomes

Start date: January 3, 2022
Phase: Phase 4
Study type: Interventional

The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for unfavourable outcomes.

NCT ID: NCT06058507 Completed - Stroke Clinical Trials

"Carotid Web Incidence and Radiological Classification, Determination of Its Relationship With Ischemic Stroke"

Start date: April 19, 2022
Phase:
Study type: Observational

In our research, we aim to increase awareness on this issue by classifying the frequency of carotid webs and their radiological classification; Evaluating the clinical data and vascular risk factors of carotid web cases and determining their relationship with ischemic stroke and determining the measures that can be taken for future optimal treatment. We aimed to contribute to their approach.

NCT ID: NCT06048055 Completed - Stroke, Ischemic Clinical Trials

Effect of Transcutaneous Vagus Nerve Stimulation on Upper Limb Function in Stroke Patients

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The goal of this interventional study is to investigate the therapeutic efficacy of non-invasive vagus nerve stimulation on upper limb function in chronic stroke patients . The main question is: •Is there a significant effect of non-invasive vagal nerve stimulation on upper limb motor function in stroke patients? Participants will be assigned into two groups. They will receive 12 sessions of true or sham transcutaneous auricular vagus nerve stimulation for 30 minutes immediately followed by 30 minutes of selected physical therapy program, three sessions per week for four weeks.

NCT ID: NCT06043856 Completed - Stroke Clinical Trials

Translation and Psychometric Analysis of the Urdu Version of Stroke Specific Quality of Life Scale

Start date: December 10, 2021
Phase:
Study type: Observational

The leading cause of adult disability globally is stroke. Although stroke is rated as the third major cause of mortality in wealthy nations, it is the second major cause of mortality in developing nations. When creating a questionnaire for use in a different context, a procedure known as "cross-cultural adaptation" takes into account both linguistic (translation) and cultural adaption concerns. Beaten guidelines are standard to develop a questionnaire into a new language, measure it's psychometric properties and culturally adapt into a new population. By Williams, Weinberger, Harris, and Clark in 1999, the SS-QOL was published and verified for the first time. Since the Stroke Specific quality of life (SS-QOL) is meant to be self-administered, no training is necessary. According to one study, stroke victims can be accurately measured using the scale over the phone. The SS-QOL scale may be finished in 10 to 15 minutes. The SS QOL score increases with improved functioning. Cronbach's alpha values varied from satisfactory (alpha = 0.75 for the work/productivity subscale) to outstanding (alpha = 0.89 for self-care) in Williams' et al. (1999a) investigation of the internal consistency of the SS-QOL in 34 stroke patients, indicating that the SS-QOL has a good internal consistency. The present study endeavors to address this gap by translating the Stroke Specific Quality of Life questionnaire into Urdu, enabling a culturally adapted and accessible assessment tool. By assessing the validity of the obtained scores within the Pakistani population, this study aims to establish the reliability and effectiveness of the Urdu version. Consequently, this will serve to bridge the literature gap in stroke-related quality of life assessments among Urdu speakers in Pakistan. In doing so, this research strives to provide valuable insights and a comprehensive tool for clinical setups across diverse settings, urban or rural. By introducing a standardized gold standard test, healthcare professionals can confidently make accurate diagnoses and prognoses for their stroke patients. The Stroke Specific Quality of Life questionnaire, with its 49 self-report items encompassing 12 energy-related domains, is poised to contribute substantially to a more thorough understanding of stroke's impact on the quality of life within the Urdu-speaking population.

NCT ID: NCT06018090 Completed - Atrial Fibrillation Clinical Trials

Microembolic Detection in Acute Ischemic Stroke Patients With Atrial Fibrillation and Outcome

Start date: June 6, 2019
Phase:
Study type: Observational [Patient Registry]

This multicenter international prospective cohort study will include patients with AIS with a known or newly diagnosed anticoagulant-naïve AF. All centers will use the same transcranial Doppler machine for one-hour monitoring with bilateral 2-MHz probes within 24 hours of symptom onset. Recordings will be analyzed for MES by a blinded central reader. The primary aim is to determine the proportion of patients with MES and the association of MES with functional outcomes assessed by a modified Rankin scale (mRS) score at 90 days.

NCT ID: NCT06005636 Completed - Ischemic Stroke Clinical Trials

Post-stroke Delirium in Ischemic Stroke Patients

Start date: September 1, 2021
Phase:
Study type: Observational

This study is to investigate the predictors of post-stroke delirium, develop and validate a nomogram of post-stroke delirium in the ischemic stroke patients.

NCT ID: NCT05996978 Completed - Ischemic Stroke Clinical Trials

Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis

Start date: February 1, 2020
Phase:
Study type: Observational

To observe the safety and efficacy of intensive drug therapy for ischemic stroke caused by severe intracranial arterial stenosis.Patients with acute stroke caused by intracranial arterial stenosis (stenosis rate ≥70%) were enrolled and accept dual antiplatelet therapy (DAPT) (aspirin 100 mg/d and clopidogrel 75 mg/d for 90 days, followed by aspirin 100 mg/d for long term) under the guidance of platelet function analysis (Verifynow) combined with the intensive statin therapy (40 mg/d for 14 days, followed by 20 mg/d for long term).